DBV Technologies Initiates VIPES Phase IIb Clinical Study, the First Global Trial Ever in Desensitization of Peanut-Allergic Children and Adults
8/2/2012 10:43:28 AM
BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today that the first patient has been enrolled, on July 31st, in the VIPES phase IIb clinical study (Double-Blind, Placebo-Controlled, Randomized Phase IIb trial to study VIaskin® Peanut’s Efficacy and Safety in peanut allergy). VIPES is a 12-month, multicenter and multinational study conducted in Europe and in North America, encompassing 6 countries, with a total of approximately 20 to 25 Investigators. The 220 Peanut-allergic subjects will range from 6 to 55 years of age with a history of immediate hypersensitive reaction to peanut protein. VIPES was granted Fast Track designation by the Food and Drug Administration (‘FDA’) and is part of a development plan with 3 clinical studies ongoing in the coming months.
comments powered by